Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 7/20 | 0.75 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 9/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533901 | 0.90 | NTRK1 (0.75) | NTRK1ROCK2ABL1PSMB5 | |
| SCHEMBL15533843 | 0.85 | NTRK1 (1.00) | NTRK1ROCK2ABL1PSMB5 | |
| SCHEMBL15533512 | 0.84 | NTRK1 (0.68) | NTRK1ROCK2ABL1 | |
| SCHEMBL15533170 | 0.83 | NTRK1 (0.77) | NTRK1ROCK2ABL1PSMB5 | |
| SCHEMBL15533183 | 0.83 | NTRK1 (0.71) | NTRK1ROCK2ABL1PSMB5 | |
| SCHEMBL15533679 | 0.83 | NTRK1 (0.71) | NTRK1ROCK2ABL1PSMB5 | |
| SCHEMBL15534957 | 0.83 | NTRK1 (0.71) | NTRK1ROCK2ABL1PSMB5 | |
| SCHEMBL15532868 | 0.82 | NTRK1 (0.68) | NTRK1ROCK2ABL1 | |
| SCHEMBL15534089 | 0.82 | NTRK1 (0.71) | NTRK1ROCK2ABL1 | |
| SCHEMBL15533015 | 0.82 | NTRK1 (0.73) | NTRK1ROCK2ABL1PSMB5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | claimed |
| EP-2858501-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | claimed |
| WO-2013176970-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2013-11-28 | — | — | WO | claimed |
| US-9181261-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181261-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | NGF, NGFR, NTRK1 | NTRK1 3/4885ROCK2 1634/4885ABL1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.